Abstract

1. Gayet-Ageron A, Prieto-Merino D, Ker K et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; 391: 125–32. 2. Rizoli S, Nascimento B Jr, Key N et al. Disseminated intravascular coagulopathy in the first 24 hours after trauma: the association between ISTH score and anatomopathologic evidence. J. Trauma 2011; 71 (5 Suppl. 1): S441–7. 3. Longstaff C, Gaffney PJ. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry 1991; 30: 979–86. 4. Silva MM, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue-type plasminogen activator. J. Thromb. Haemost. 2012; 10: 2354–60. 5. Hijazi N, Abu Fanne R, Abramovitch R et al. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 2015; 125: 2558–67. 6. Longstaff C, Locke M. Increased urokinase and consumption of alpha2-antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay. J. Thromb. Haemost. 2019; 17: 195–205.